Biogen Ma Inc.

Biogen Idec Ma Inc.

Sunesis Pharmaceuticals, Inc.

Bin Ma

Gnanasambandam Kumaravel

Kevin Guckian

Arthur G Taveras

Edward Yin-Shiang Lin

Guo Zhu Zheng

Richard Dana Caldwell

Jermaine Thomas

Brian T Hopkins

Lei Zhang

Lihong Sun

Xiaogao Liu

Sha Mi

Joseph P Lyssikatos

Zhili Xin

Isaac E Marx

Robin Prince

Daniel M Scott

Wen-Cherng Lee

Zhan Shi

Timothy Raymond Chan

Hairuo Peng

Zhaohui Shao

Hua Miao

Kevin Koch

Matthew Lynn Peterson

Fengmei Zheng

Daniel B Patience

Deping Wang

Marta Nevalainen

Jürgen Schulz

Jianhua Chao

Kevin Lewis Otipoby

Michael A Dechantsreiter

Andrea Bertolotti-Ciarlet

Kevin M Guckian

Provided are compounds of Formula (I): Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, A, B, B, Qand Qare as defined herein; and methods for their use and production.

Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Inhibiting agents for Bruton's tyrosine kinase

Inhibiting agents for bruton's tyrosine kinase

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Biaryl inhibitors of Bruton's tyrosine kinase

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

S1P modulating agents

Biaryl inhibitors of Bruton'S tyrosine kinase

Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

SIP modulating agents

Biaryl bruton's tyrosine kinase inhibitors

Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

Compounds that are S1P modulating agents and/or ATX modulating agents

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Bicyclic aryl sphingosine 1-phosphate analogs

Growing community of inventors

Arlington, MA, United States of America

Bin Ma